Researchers develop a method to label GlcNAc residues of N-glycans in yeast with high specificity and efficiency. The study of protein structure and function, both in vitro and in vivo ...

Precision Biologics will present affinity maturation and characterization of a novel core 2 O-glycan epitope targeting anti-human carcinoma mAb PB-223 at the Society for Immunotherapy of Cancer ...

GlycoNex, Inc. (4168, hereinafter referred to as GNX), a clinical stage biotechnology company focused on the development of ...

By dissecting the role of mucin's protein and glycan components, researchers reveal the complex interactions between diet and gut bacteria, offering insights for future therapeutic applications.

About GlycoNex Inc. GlycoNex Inc. is a clinical-stage biotechnology company focused on the development of glycan-directed cancer immunotherapies that effectively inhibit tumor growth while minimizing ...

is a clinical-stage biotechnology company focused on the development of glycan-directed cancer immunotherapies ... a humanized monoclonal antibody (mAB) designed to target abnormal sugar molecules ...